Tacere Therapeutics develops human therapeutics based on RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. Using this approach, the drugs we create promise long term treatment or cure with a single dose.
Tacere Therapeutics is a Benitec Biopharma company.
Our biological drugs target and silence unwanted genes, safely and with lasting effect.
TT-034, our drug to treat Hepatitis C with a single dose, is poised to commence clinical trial.
January 14, 2014
FDA advises that ‘first in man’ clinical trial of TT-34 can proceed
December 10, 2013
Third paper on mode of action of TT-034 to be published in prestigious journal
December 9, 2013
Benitec submits IND application for TT-034 to the US FDA
September 18, 2013
Benitec Corporate Profile
August 27, 2013
Dr Peter French Appointed to the Board
August 15, 2013
Hepatitis C Presentation HCV 2013